Colgate-Palmolive Q1: I Don't Think It Is Going To Outperform The Broader Index

Colgate-Palmolive posted solid Q1 results with 8.4% revenue growth, supported by strong performance outside North America. The North American segment remains a drag, with operating profit down 28% and margins pressured by tariffs and freight costs. Management is expanding the SGPP productivity program, targeting $200M-$300M in annual pretax savings by 2028 through supply chain and operational optimizations.

Analysis

The key takeaway is not the headline growth, but the widening quality gap between geographies. CL is proving it can still price and gain share in less defensive markets, while North America looks increasingly like a low-return drag where incremental freight/tariff noise is being absorbed with limited pricing power. That creates a subtle but important dynamic: the earnings base is becoming more dependent on regions with better elasticity and less promotional intensity, which should support multiple stability even if the domestic segment stays soft.

The SGPP expansion is more interesting as a medium-term margin option than as a near-term earnings driver. If management can actually convert supply chain redesign into $200m-$300m of pretax savings by 2028, that implies several hundred basis points of cumulative gross margin support relative to a flat-cost scenario, but the ramp will likely be back-end loaded and vulnerable to execution slippage. In the meantime, the market may underestimate how much offset CL can generate through productivity, which reduces the probability that North America weakness becomes a permanent earnings reset.

Second-order beneficiaries are the contract manufacturers, logistics operators, and input suppliers that can help CL re-engineer sourcing and inventory flows; the losers are domestic rivals with weaker scale and less room to absorb cost shocks. The main risk is that management uses productivity to defend volume rather than rebuild margin, which would delay EPS leverage for multiple quarters. A sharper reversal would come from relief on trade-related costs or freight normalization, which could make the current domestic profit compression look cyclical rather than structural.

Consensus likely treats this as a clean defensive staple story, but the more important question is whether the international mix improvement plus operating discipline can offset a stale North America base for long enough to matter. If the market is focused only on reported growth, it may be underpricing the option value of cost-out; if it is already assuming a full margin recovery, then the risk/reward is less attractive because the payback is spread over several years.

Key Decisions for Investors

• Stay modestly long CL on a 6-12 month horizon; the setup favors low-beta compounding, but position size should reflect that most of the productivity benefit is back-end loaded and execution risk is real.
• Use any 2-4% pullback to add to CL rather than chase strength; the near-term catalyst path is limited, but the downside is buffered if international momentum persists and the market re-rates the margin option.
• Pair trade: long CL / short a more U.S.-exposed consumer staples peer with thinner margins and less scale in procurement, targeting a 3-6 month convergence as cost inflation remains uneven.
• If you want convexity, buy 9-12 month CL calls financed by selling puts near current levels; the thesis is that a credible savings roadmap can re-anchor earnings estimates without needing a macro improvement.
• Watch for signs that North American operating profit stabilizes over the next 1-2 quarters; if not, trim the position because the market will start viewing the segment as a structural headwind rather than a temporary margin bridge.